About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Treatment of TB Patients Via Smartphone App More Effective

by Mohamed Fathima S on February 25, 2019 at 9:26 AM
Font : A-A+

Treatment of TB Patients Via Smartphone App More Effective

Treatment administered over video on a smartphone is more likely to be adhered by tuberculosis (TB) patients than through face-to-face appointments, finds a study.

Directly observed treatment (DOT) has been the standard of care for TB since the early 1990s, but it is inconvenient for patients and service providers.

Advertisement


The smartphone-enabled video-observed therapy (VOT), recommended by the World Health Organization as an alternative to DOT, is a more effective approach to TB treatment, stated the study published in The Lancet.

"VOT is likely to be preferable for many patients across a broad range of settings, providing a more acceptable, effective, cheaper option for supervision of multiple daily doses than DOT," said Andrew C. Hayward from the University College London.
Advertisement

The study tested whether levels of treatment observation were improved with VOT. The team randomly assigned 226 patients -- 112 to VOT and 114 to DOT.

Seventy eight of 112 patients on VOT achieved 80 per cent scheduled observations successfully completed during the first two months compared with 35 of 114 on DOT.

VOT also supported daily dosing, was effective for socially complex populations and had a lower drop-out rate than DOT.

The absence of face-to-face contact did not reduce the identification of adverse events or lead to more unscheduled appointments. VOT reduced staff time requirements, especially compared with home-based DOT, the study showed.

"There is an urgent global need for more effective and cheaper alternatives to DOT to enable effective ambulatory care of both drug-sensitive and MDR TB," Hayward said.

According to the US Centers for Disease Control and Prevention (CDC), TB is one of the world's deadliest diseases.

In 2017, 10 million people around the world became sick with TB disease. There were 1.3 million TB-related deaths worldwide. It is also a leading killer of people who are HIV infected.



Source: IANS
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
First Dose of COVID-19 Vaccines May Improve Mental Health
Printed Temperature Sensors help with Continuous Temperature Monitoring
Health Benefits of Giloy
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Tuberculosis AIDS/HIV Silicosis Screening Tests for Tuberculosis 

Recommended Reading
Drug-Resistant Tuberculosis
Drug-resistant tuberculosis (TB) is a globally serious infectious disease caused by the bacterium .....
Extra Pulmonary Tuberculosis
Extra pulmonary tuberculosis is infection of tissues and organs other than the lungs by ......
Renal Tuberculosis
Renal tuberculosis or tuberculosis of the kidney is a type of genitourinary tuberculosis that can .....
Screening Tests for Tuberculosis
Tuberculin skin test and Interferon - Release Assays are tests used to screen for tuberculosis....
AIDS/HIV
"AIDS is an epidemic disease, a potentially preventable, deadly infection for which there is no cure...
Silicosis
Silicosis is a lung disease caused by inhalation of crystalline free silica dust. It is characterise...
Tuberculosis
Tuberculosis, caused by Mycobacterium tuberculosis, primarily affects the lung. It may spread to oth...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use